<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS207293</article-id><article-id pub-id-type="doi">10.1101/2025.07.14.664762</article-id><article-id pub-id-type="archive">PPR1051756</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genome editing of a low-penetrance albinism-associated variant in TYR in patient-derived pluripotent stem cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Downton</surname><given-names>Polly</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Bates</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Woods</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Adamson</surname><given-names>Antony</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Sergouniotis</surname><given-names>Panagiotis I</given-names></name><xref ref-type="aff" rid="A3">c</xref><xref ref-type="aff" rid="A4">d</xref><xref ref-type="aff" rid="A5">e</xref></contrib></contrib-group><aff id="A1"><label>a</label>Genome Editing Unit, Faculty of Biology, Medicine and Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/027m9bs27</institution-id><institution>University of Manchester</institution></institution-wrap>, <city>Manchester</city>, <country country="GB">UK</country></aff><aff id="A2"><label>b</label>Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/027m9bs27</institution-id><institution>University of Manchester</institution></institution-wrap>, and <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04rrkhs81</institution-id><institution>the Manchester Academic Health Science Centre</institution></institution-wrap>, <city>Manchester</city>, <country country="GB">UK</country></aff><aff id="A3"><label>c</label>Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/027m9bs27</institution-id><institution>University of Manchester</institution></institution-wrap>, <city>Manchester</city>, <country country="GB">UK</country></aff><aff id="A4"><label>d</label>Manchester Centre for Genomic Medicine, Saint Maryâ€™s Hospital, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00he80998</institution-id><institution>Manchester University NHS Foundation Trust</institution></institution-wrap>, <city>Manchester</city>, <country country="GB">UK</country></aff><aff id="A5"><label>e</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04xtpk854</institution-id><institution>Manchester Royal Eye Hospital</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00he80998</institution-id><institution>Manchester University NHS Foundation Trust</institution></institution-wrap>, <city>Manchester</city>, <country country="GB">UK</country></aff><pub-date pub-type="nihms-submitted"><day>17</day><month>07</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>16</day><month>07</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1"><italic>TYR</italic> encodes tyrosinase, the enzyme catalysing the initial steps of melanin biosynthesis in melanocytes and retinal pigment epithelia (RPE). <italic>TYR</italic> c.1205G&gt;A (p.Arg402Gln) is a common genetic variant associated with several pigmentation traits. Notably, when this variant is encountered in specific haplotypic backgrounds in the homozygous state, it predisposes to albinism. We generated an induced pluripotent stem cell (iPSC) line from an affected individual carrying such a homozygous genotype (UMANi255-A), and then used CRISPR-Cas9 to correct the <italic>TYR</italic> c.1205G&gt;A variant (UMANi255-A-1). The resulting iPSC lines demonstrate capacity for multi-lineage differentiation, providing a useful in vitro model for studying pigmentation biology.</p></abstract></article-meta></front><body><sec id="S1"><label>1</label><title>Resource Table</title><p id="P2"><table-wrap id="T3" orientation="portrait" position="anchor"><table frame="box" rules="groups"><tbody><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Unique stem cell line identifier</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">UMANi255-A<break/>UMANi255-A-1</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Alternative name(s) of stem cell line</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">NB221c<break/>PS02b-B6</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Institution</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Faculty of Biology, Medicine and Health, University of Manchester</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000"><bold>Contact information of the reported cell line distributor</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Panagiotis Sergouniotis<break/>(<email>panagiotis.sergouniotis@manchester.ac.uk</email>)</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Type of cell line</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">iPSC with subsequent genetic modification</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid"><bold>Origin</bold></td><td valign="top" align="left" style="border: 1px solid">Human</td></tr><tr><td valign="top" align="left" style="border-left: 1px solid"><bold>Additional origin info <italic>(applicable for human ESC or iPSC)</italic></bold></td><td valign="top" align="left" style="border-left: 1px solid #000000;border-right: 1px solid">Age: 16 y.o.<break/>Sex: Female<break/>Ethnicity/genetic background information: white European-like ancestries</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Cell Source</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Blood (PBMCs, Ficoll preparation)</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Method of reprogramming</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">CytoTune 2 (non-integrating Sendai Virus)</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Clonality</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Clonal, isolation by single colony selection</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000"><bold>Evidence of the reprogramming transgene loss (including genomic copy if applicable)</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">PCR for loss of Sendai virus</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>The cell culture system used</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Essential 8 medium, culture on vitronectin-coated plates</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Type of the Genetic Modification</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Mutation correction by CRISPR/Cas9-mediated homology directed repair</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Associated disease</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Oculocutaneous albinism type 1 (OCA1) [OMIM #203100]</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Gene/locus modified in the reported transgenic line</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">TYR: c.1205G&gt;A (p.Arg402Gln); chr11:89284793 (GRCh38.p14); rs1126809</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000"><bold>Method of modification / user-customisable nucleases (UCN) used, the resource used for design optimisation</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AltR HiFi Sp Cas9 V3 gRNAs designed using CRISPOR</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000"><bold>User-customisable nuclease (UCN) delivery method</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Ribonucleoprotein complex</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000"><bold>All double-stranded DNA genetic material molecules introduced into the cells</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Sendai vectors (reprogramming)</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000"><bold>Evidence of the absence of random integration of any plasmids or DS DNA introduced into the cells.</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">PCR against Sendai vectors</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Analysis of the nuclease-targeted allele status</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Sanger sequencing of PCR products spanning target sites, sequence deconvolution by ICE analysis</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Homozygous allele status validation</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">qPCR copy number analysis of targeted regions of gDNA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000"><bold>Method of the off-target nuclease activity prediction and surveillance</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Targeted Sanger sequencing of top 5 predicted off-target sites</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid"><bold>Ethical/GMO work approvals</bold></td><td valign="top" align="left" style="border: 1px solid">Relevant approvals were obtained from the following UK National Healthcare Service (NHS) Research Ethics Committees (REC): North West - Greater Manchester East REC (REC reference: 22/NW/0336); Yorkshire &amp; The Humber - Bradford Leeds REC (REC reference 15/YH/0365)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="S2"><label>2</label><title>Resource Utility</title><p id="P3"><italic>TYR</italic> c.-301C&gt;T [rs4547091], c.575C&gt;A (p.Ser192Tyr) [rs1042602] and c.1205G&gt;A (p.Arg402Gln) [rs1126809] are three common variants impacting tyrosinase. One of the haplotypes that they form, <italic>TYR</italic> c.[-301C;575C&gt;A;1205G&gt;A], has been associated with albinism. Here, we report two iPSC lines that enable functional dissection of this complex haplotype in a physiologically relevant cellular context.</p></sec><sec id="S3"><label>3</label><title>Resource Details</title><p id="P4">Albinism is a clinically and genetically heterogeneous group of conditions characterised by reduced levels of melanin pigment and a spectrum of developmental visual system anomalies that typically result in impaired vision. Hypopigmentation of the hair and skin is common and most affected individuals have an increased risk of developing skin cancer. At least 20 genes have been implicated in albinism, with biallelic variants in <italic>TYR</italic> accounting for one of the most prevalent subtypes (<xref ref-type="bibr" rid="R3">Lasseaux et al. 2018</xref>; <xref ref-type="bibr" rid="R8">Wei et al. 2022</xref>).</p><p id="P5">The most commonly encountered albinism-implicated variant is <italic>TYR</italic> c.1205G&gt;A (p.Arg402Gln) [rs1126809]. Although this missense variant is common (with up to 40% heterozygosity and ~8% homozygosity in populations of European-like ancestries), it has been suspected to have a role in mild forms of albinism since 1991 (<xref ref-type="bibr" rid="R6">Monferme et al. 2019</xref>). Notably, recent studies have shown that the phenotypic effect of <italic>TYR</italic> c.1205G&gt;A can be modified by another common <italic>TYR</italic> missense variant, c.575C&gt;A (p.Ser192Tyr) [rs1042602] and/or by a <italic>TYR</italic> promoter variant, c.-301C [rs4547091] (<xref ref-type="bibr" rid="R2">Jagirdar et al. 2014</xref>; <xref ref-type="bibr" rid="R5">Michaud et al. 2022</xref>; <xref ref-type="bibr" rid="R4">Lin et al. 2022</xref>). While prior studies assessed the individual impact of these variants when overexpressed in heterologous systems (<xref ref-type="bibr" rid="R2">Jagirdar et al. 2014</xref>; <xref ref-type="bibr" rid="R7">Reinisalo et al. 2012</xref>) an in-depth in vitro evaluation of their combined effects in an endogenous context is lacking.</p><p id="P6">To investigate combined variant effects, we generated an induced pluripotent stem cell (iPSC), UMANi255-A. This was derived from an individual with signs of albinism, including foveal hypoplasia and nystagmus, homozygous for the <italic>TYR</italic> c.[-301C;575C&gt;A;1205G&gt;A] haplotype (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). Using CRISPR-Cas9 genome editing, we then corrected the c.1205G&gt;A variant to c.1205G, creating an isogenic line homozygous for the <italic>TYR</italic> c.[-301C;575C&gt;A;1205G] haplotype. This model enables the investigation of the combined impact of these variants on melanin synthesis in relevant cell types, including retinal pigment epithelial (RPE) cells and melanocytes.</p><p id="P7">UMANi255-A cells were nucleofected with Cas9 nuclease complexed with a single-guide RNA (sgRNA) targeting the c.1205 site and a single-stranded oligodeoxynucleotide (ssODN) repair template for homology-directed repair (HDR) with the aim of introducing an A-to-G conversion (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). After characterisation of the mixed population (<xref ref-type="supplementary-material" rid="SD1">Fig. S1B</xref>), several clonal lines were expanded and characterised to identify a validated homozygous edited population.</p><p id="P8">All generated lines exhibited typical iPSC morphology (<xref ref-type="fig" rid="F1">Fig. 1C</xref>) and expressed pluripotency markers, confirmed via immunofluorescence staining (OCT4, SSEA4, NANOG, PODXL) (<xref ref-type="fig" rid="F1">Fig. 1D</xref>) and qRT-PCR (OCT4, SOX2), with expression levels comparable to the parental line and significantly higher than in HEK293T cells (<xref ref-type="fig" rid="F1">Fig. 1E</xref>). Short tandem repeat (STR) analysis confirmed the derivation of UMANi255-A-1 from the parental UMANi255-A line, and karyotyping was unremarkable (<xref ref-type="fig" rid="F1">Fig. 1F</xref>).</p><p id="P9">The differentiation potential of the edited lines was demonstrated through directed differentiation into all three germ layers, verified by immunofluorescence staining for endodermal (SOX17, FOXA2), ectodermal (OTX2, Î²-tubulin III), and mesodermal (Brachyury, Î±-SMA) markers (<xref ref-type="fig" rid="F1">Fig. 1G</xref>). No off-target genome editing events were detected (<xref ref-type="supplementary-material" rid="SD1">Fig. S1D</xref>).</p><p id="P10">This isogenic iPSC model provides a powerful system to dissect the consequences of <italic>TYR</italic> dysfunction and will facilitate future studies into the role of melanin synthesis on visual system development.</p></sec><sec id="S4" sec-type="materials | methods"><label>4</label><title>Materials and Methods</title><sec id="S5"><label>4.1</label><title>Cell reprogramming and culture</title><p id="P11">Whole blood samples were layered over Ficoll-Paque (GE Healthcare) then subjected to density gradient centrifugation for PBMC isolation. Washed PBMCs were expanded for eight days using the Erythroid Reprogramming kit (STEMCELL Technologies, 05924). Erythroid progenitors (approx. 5 x 10<sup>4</sup>) were transduced using CytoTune iPS 2.0 Sendai virus (Invitrogen, A16517). Five days after transduction cells were transferred to ReproTeSR medium and maintained for at least 10 days prior to manual colony picking. Cells were maintained in TeSR E8 medium (STEMCELL Technologies, 05990), refreshed every 1-2 days, on Vitronectin-coated plates (Gibco, A14700) for 12-15 passages before characterisation and use. Cells were passaged following dissociation with EDTA (500 nM). For cryopreservation, cells were slowly cooled to -80Â°C in freezing medium (Gibco, A26444). Media was supplemented with RevitaCell (Gibco, A26445) for 24 hours after thawing.</p></sec><sec id="S6"><label>4.2</label><title>CRISPR-Cas9 editing</title><p id="P12">Genome editing gRNAs were designed using CRISPOR (<xref ref-type="bibr" rid="R1">Concordet and Haeussler 2018</xref>). Approx. 5 x 10<sup>5</sup> cells were resuspended in buffer P3 containing precomplexed sgRNA and Cas9 nuclease and an ssODN repair template. Nucleofection used a 4D-Nucleofector system, programme CM150 (Lonza). Cells were seeded into vitronectin-coated dishes in media supplemented with RevitaCell, cloneR (STEMCELL Technologies, 05888), TSA (10 nM, Cell Guidance Systems, SM36-1) and M3814 (500 nM, Selleckchem, S8586) for 24 hours. Clones were isolated by manual picking of colonies.</p></sec><sec id="S7"><label>4.3</label><title>Genotype analysis</title><p id="P13">Genomic DNA was extracted using the PureLink Genomic DNA mini kit (ThermoFisher Scientific, K182001). PCR amplicons were generated using KOD polymerase (Merck, 71086-3). Amplicons were analysed using a QIAxcel electrophoresis system (Qiagen) then purified using the SmartPure gel DNA purification kit (Eurogentec, SK-GEPU-100). Amplicons were sequenced by Genewiz and modification efficiency analysed by ICE (Synthego). Copy number at the modified locus was determined using custom primers and GoScript qPCR mastermix (Promega, A6002). A TaqMan reference assay targeting <italic>TERT</italic> and Genotyping Mastermix (Applied Biosystems, 4403316 and 4371353) were used for normalisation.</p></sec><sec id="S8"><label>4.4</label><title>Immunofluorescence staining</title><p id="P14">Cells were seeded in 24 well plates pre-coated with vitronectin (pluripotency analysis) or Matrigel (differentiation analysis; Fisher Scientific, 11573560). Differentiation used the Human Pluripotent Stem Cell Functional Identification Kit (R&amp;D Systems, SC027B). Cells were washed then fixed with 4% paraformaldehyde (15 min, RT). Fixed cells were permeabilised and blocked with 0.1% Triton X-100, 1% BSA, 10% donkey serum (45 min, RT), incubated with primary antibodies (overnight, 4Â°C), then washed and incubated with secondary antibodies (1h, RT). Nuclei were counterstained with DAPI (Merck, D9542-5MG). Cells were imaged using a BX51 microscope (Olympus) with a Q-Imaging camera and Q-Capture Pro software (Micro Imaging Applications Group).</p></sec><sec id="S9"><label>4.5</label><title>Additional validation</title><p id="P15">RNA for pluripotency expression analysis was isolated using the ReliaPrep RNA Cell miniprep system prior to cDNA conversion using GoScript Reverse Transcription system (both Promega). Expression analysis used GoTaq qPCR mastermix (Promega) on a QuantStudio 3 instrument (Applied Biosystems). Sendai viral clearance was confirmed by PCR and QIAxcel quantification following RNA extraction and cDNA conversion. Mycoplasma-free status and genetic identity confirmation used the Eurofins Mycoplasmacheck and Cell Type Authentication services. Karyotype analysis was performed by Cell Guidance Systems.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary File 1</label><media xlink:href="EMS207293-supplement-Supplementary_File_1.pdf" mimetype="application" mime-subtype="pdf" id="d2aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S10"><title>Acknowledgements</title><p>This research is co-funded by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308) and the Wellcome Trust (224643/Z/21/Z, Clinical Research Career Development Fellowship to P.I.S.). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The authors would like to thank the University of Manchester Genome Editing Unit (especially Ms Muskan Gupta) and Bioimaging Core Facilities for experimental support, and to acknowledge the help of Mr Steve Haynes and Professor Sue Kimber at the University of Manchester, UK.</p></ack><fn-group><fn id="FN1" fn-type="con"><p id="P16"><bold>Authorship contribution statement (CRediT taxonomy)</bold></p><p id="P17">Conceptualisation â€“ PD, AA, PIS; Methodology â€“ PD, NB, SW; Investigation â€“ PD, NB. Writing â€“ Original Draft â€“ PD, NB, PIS; Writing â€“ Review &amp; Editing â€“ PD, NB, SW, AA, PIS; Supervision â€“ AA, PIS; Project Administration - PIS; Funding Acquisition - PIS.</p></fn></fn-group><ref-list><ref id="R1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concordet</surname><given-names>JP</given-names></name><name><surname>Haeussler</surname><given-names>M</given-names></name></person-group><article-title>CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><fpage>W242</fpage><lpage>W45</lpage><pub-id pub-id-type="doi">10.1093/nar/gky354</pub-id><pub-id pub-id-type="pmcid">PMC6030908</pub-id><pub-id pub-id-type="pmid">29762716</pub-id></element-citation></ref><ref id="R2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagirdar</surname><given-names>K</given-names></name><name><surname>Smit</surname><given-names>DJ</given-names></name><name><surname>Ainger</surname><given-names>SA</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Brown</surname><given-names>DL</given-names></name><name><surname>Chapman</surname><given-names>B</given-names></name><name><surname>Zhen Zhao</surname><given-names>Z</given-names></name><name><surname>Montgomery</surname><given-names>GW</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Stow</surname><given-names>JL</given-names></name><name><surname>Duffy</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Molecular analysis of common polymorphisms within the human Tyrosinase locus and genetic association with pigmentation traits</article-title><source>Pigment Cell Melanoma Res</source><year>2014</year><volume>27</volume><fpage>552</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12253</pub-id><pub-id pub-id-type="pmcid">PMC4119297</pub-id><pub-id pub-id-type="pmid">24739399</pub-id></element-citation></ref><ref id="R3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasseaux</surname><given-names>E</given-names></name><name><surname>Plaisant</surname><given-names>C</given-names></name><name><surname>Michaud</surname><given-names>V</given-names></name><name><surname>Pennamen</surname><given-names>P</given-names></name><name><surname>Trimouille</surname><given-names>A</given-names></name><name><surname>Gaston</surname><given-names>L</given-names></name><name><surname>Monferme</surname><given-names>S</given-names></name><name><surname>Lacombe</surname><given-names>D</given-names></name><name><surname>Rooryck</surname><given-names>C</given-names></name><name><surname>Morice-Picard</surname><given-names>F</given-names></name><name><surname>Arveiler</surname><given-names>B</given-names></name></person-group><article-title>Molecular characterization of a series of 990 index patients with albinism</article-title><source>Pigment Cell Melanoma Res</source><year>2018</year><volume>31</volume><fpage>466</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">29345414</pub-id></element-citation></ref><ref id="R4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Sanchez-Bretano</surname><given-names>A</given-names></name><name><surname>Leslie</surname><given-names>JS</given-names></name><name><surname>Williams</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Thomas</surname><given-names>NS</given-names></name><name><surname>Callaway</surname><given-names>J</given-names></name><name><surname>Deline</surname><given-names>J</given-names></name><name><surname>Ratnayaka</surname><given-names>JA</given-names></name><name><surname>Baralle</surname><given-names>D</given-names></name><name><surname>Schmitt</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Evidence that the Ser192Tyr/Arg402Gln in cis Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B)</article-title><source>NPJ Genom Med</source><year>2022</year><volume>7</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1038/s41525-021-00275-9</pub-id><pub-id pub-id-type="pmcid">PMC8758782</pub-id><pub-id pub-id-type="pmid">35027574</pub-id></element-citation></ref><ref id="R5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaud</surname><given-names>V</given-names></name><name><surname>Lasseaux</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>DJ</given-names></name><name><surname>Gerrard</surname><given-names>DT</given-names></name><name><surname>Plaisant</surname><given-names>C</given-names></name><collab>U K Biobank Eye, Consortium Vision</collab><name><surname>Fitzgerald</surname><given-names>T</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Arveiler</surname><given-names>B</given-names></name><name><surname>Black</surname><given-names>GC</given-names></name><etal/></person-group><article-title>The contribution of common regulatory and protein-coding TYR variants to the genetic architecture of albinism</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><elocation-id>3939</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-31392-3</pub-id><pub-id pub-id-type="pmcid">PMC9270319</pub-id><pub-id pub-id-type="pmid">35803923</pub-id></element-citation></ref><ref id="R6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monferme</surname><given-names>S</given-names></name><name><surname>Lasseaux</surname><given-names>E</given-names></name><name><surname>Duncombe-Poulet</surname><given-names>C</given-names></name><name><surname>Hamel</surname><given-names>C</given-names></name><name><surname>Defoort-Dhellemmes</surname><given-names>S</given-names></name><name><surname>Drumare</surname><given-names>I</given-names></name><name><surname>Zanlonghi</surname><given-names>X</given-names></name><name><surname>Dollfus</surname><given-names>H</given-names></name><name><surname>Perdomo</surname><given-names>Y</given-names></name><name><surname>Bonneau</surname><given-names>D</given-names></name><name><surname>Korobelnik</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Mild form of oculocutaneous albinism type 1: phenotypic analysis of compound heterozygous patients with the R402Q variant of the TYR gene</article-title><source>Br J Ophthalmol</source><year>2019</year><volume>103</volume><fpage>1239</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">30472657</pub-id></element-citation></ref><ref id="R7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinisalo</surname><given-names>M</given-names></name><name><surname>Putula</surname><given-names>J</given-names></name><name><surname>Mannermaa</surname><given-names>E</given-names></name><name><surname>Urtti</surname><given-names>A</given-names></name><name><surname>Honkakoski</surname><given-names>P</given-names></name></person-group><article-title>Regulation of the human tyrosinase gene in retinal pigment epithelium cells: the significance of transcription factor orthodenticle homeobox 2 and its polymorphic binding site</article-title><source>Mol Vis</source><year>2012</year><volume>18</volume><fpage>38</fpage><lpage>54</lpage><pub-id pub-id-type="pmcid">PMC3258524</pub-id><pub-id pub-id-type="pmid">22259223</pub-id></element-citation></ref><ref id="R8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>Z</given-names></name><name><surname>Bai</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Spectrum Analysis of Albinism Genes in a Large Cohort of Chinese Index Patients</article-title><source>J Invest Dermatol</source><year>2022</year><volume>142</volume><fpage>1752</fpage><lpage>55</lpage><elocation-id>e3</elocation-id><pub-id pub-id-type="pmid">34838614</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><graphic xlink:href="EMS207293-f001"/></fig><fig id="F2" position="float"><graphic xlink:href="EMS207293-f002"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characterization and validation</title></caption><table frame="box" rules="groups"><thead><tr><th valign="top" align="center" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Classification</th><th valign="top" align="center" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Output type</th><th valign="top" align="center" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Result</th><th valign="top" align="center" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Data</th></tr></thead><tbody><tr><td valign="middle" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000"><bold>Schematic of a transgene/genetic modification</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Schematics illustrating position of <italic>TYR</italic> variants and guide target location for CRISPR-Cas9 modification modification</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Variant sequences and correction confirmed.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="fig" rid="F1">Figure 1A,B</xref></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Morphology</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Photography</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Bright Field images show typical pluripotent stem cell morphlogy.<break/>Magnification 10X, scale bar = 100 Î¼m.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="fig" rid="F1">Figure 1C</xref></td></tr><tr><td valign="top" align="left" rowspan="2" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Pluripotency status evidence for the described cell line</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Qualitative analysis by ICC</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Expression of pluripotency markers (NANOG, OCT4, SSEA, PODXL) confirmed by ICC. Magnification 20X, scale bar = 100 Î¼m.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="fig" rid="F1">Figure 1D</xref></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Quantitative analysis by qRT-PCR</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Expression of pluripotency marker transcripts (<italic>OCT4, SOX2</italic>) confirmed.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="fig" rid="F1">Figure 1E</xref></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Karyotype</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Karyotype (G-banding)</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">46XX,<break/>Resolution 400-450 bhps<break/>46XX,<break/>Resolution 350-450 bhps</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="fig" rid="F1">Figure 1F</xref></td></tr><tr><td valign="top" align="left" rowspan="2" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid"><bold>Genotyping for the desired genomic alteration/allelic status of the gene of interest</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PCR from gDNA, Sanger sequencing</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Presence of variants and subsequent correction confirmed by Sanger sequencing of PCR from gDNA.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="fig" rid="F1">Figure 1A,B</xref></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">Copy number analysis to evaluate homozygous status of introduced genomic alteration.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">Copy number equivalent to parental cell gDNA.</td><td valign="top" align="left" style="border: 1px solid"><xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1C</xref></td></tr><tr><td valign="top" align="left" style="border-left: 1px solid"><bold>Parental and modified cell line genetic identity evidence</bold></td><td valign="top" align="left" style="border-left: 1px solid">STR analysis</td><td valign="top" align="left" style="border-left: 1px solid">STR profile of 16 loci, identical for both cell lines.</td><td valign="top" align="left" style="border-left: 1px solid #000000;border-right: 1px solid">Supplementary File 2, <italic><styled-content style="color:#808080">submitted to journal archive</styled-content></italic></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Mutagenesis / genetic modification outcome analysis</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Sequencing (genomic DNA PCR or RT-PCR product)</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Presence of variants and subsequent correction confirmed by Sanger sequencing of PCR from gDNA.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="fig" rid="F1">Figure 1A,B</xref></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Off-target nuclease activity analysis</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PCR across top 5 predicted likely off-target sites</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">No modification detected at off-target sites. Parental and modified sequences identical.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1D</xref></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Specific pathogen-free status</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Mycoplasma</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Mycoplasmacheck service report negative for all lines.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="supplementary-material" rid="SD1">Supplementary File 1</xref></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><bold>Multilineage differentiation potential</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Directed differentiation;<break/>ICC.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Expression of endoderm (SOX17, FOXA2), ectoderm (OTX2, TUBB3) and mesoderm (BRACHYURY, aSMA) markers confirmed by ICC.</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><xref ref-type="fig" rid="F1">Figure 1G</xref></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid"><bold><italic>Outcomes of gene editing experiment (OPTIONAL)</italic></bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">Genomic editing efficiency</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">PS02b HDR efficiency 41% at pool level; 24 clones established, including 5 unedited, 5 potential homozygous and 2 potential heterozygous.</td><td valign="top" align="left" style="border: 1px solid"><xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1B</xref></td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Reagents details</title></caption><table frame="box" rules="groups"><thead><tr><th valign="top" align="left" colspan="4" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Antibodies and stains used for immunocytochemistry/flow-cytometry</th></tr><tr><th valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"/><th valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Antibody</th><th valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Dilution</th><th valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Company Cat # and RRID</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="6" style="border-top: 1px solid #000000;border-left: 1px solid">Pluripotency markers</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-OCT4, goat IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">10 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC009, RRID: AB_3698061</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-NANOG, goat IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">10 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC009, RRID: AB_3698061</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-SOX2, mouse IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">10 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC009, RRID: AB_3698061</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-SSEA1, mouse IgM</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">10 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC009, RRID: AB_3698061</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-PODXL, mouse IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">10 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC009, RRID: AB_3698061</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-SSEA4, mouse IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">10 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC009, RRID: AB_3698061</td></tr><tr><td valign="top" align="left" rowspan="6" style="border-top: 1px solid #000000;border-left: 1px solid">Differentiati on markers</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-OTX2, goat IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">1 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC027B, RRID: AB_3674636</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-Î²-TUBULIN, mouse IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">1:100</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# MAB1195, RRID: AB_357520</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-FOXA2, rabbit IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">1:200</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">CST cat# 8186, RRID: AB_10891055</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-SOX17, goat IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">1 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC027B, RRID: AB_3674636</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-Î±-SMA, mouse IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">1:100</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# MAB1420, RRID: AB_262054</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Anti-BRACHYURY, goat IgG</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">1 Î¼g/ml</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Bio-Techne cat# SC027B, RRID: AB_3674636</td></tr><tr><td valign="top" align="left" rowspan="5" style="border-top: 1px solid #000000;border-left: 1px solid">Secondary antibodies</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Donkey anti-Goat IgG, Alexa Fluor 488</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">1:200</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Thermo Fisher Scientific cat# A-11055, RRID: AB_2534102</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Donkey anti-Mouse IgG,<break/>Alexa Fluor 488</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">1:200</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Thermo Fisher Scientific cat# A-21202, RRID: AB_141607</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">Donkey anti-Rabbit IgG, Alexa Fluor 488</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">1:200</td><td valign="top" align="left" style="border: 1px solid #000000">Thermo Fisher Scientific cat# A-21206, RRID: AB_2535792</td></tr><tr><td valign="top" align="left" style="border-left: 1px solid #000000">Donkey anti-Goat IgG, Alexa Fluor 594</td><td valign="top" align="left" style="border-left: 1px solid">1:200</td><td valign="top" align="left" style="border-left: 1px solid #000000;border-right: 1px solid #000000">Thermo Fisher Scientific cat# A-11058, RRID: AB_2534105</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Donkey anti-Mouse IgG,<break/>Alexa Fluor 594</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">1:200</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Thermo Fisher Scientific cat# A-21203, RRID: AB_2535789</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Nuclear stain</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">DAPI</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">1 Î¼g/mL</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Thermo Fisher Scientific cat# 62248</td></tr><tr><td valign="top" align="left" colspan="4" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000"><bold>Site-specific nuclease</bold></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Nuclease information</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">AltR HiFi Sp Cas9 V3</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Integrated DNA Technologies, cat# 1081061</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Delivery method</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Nucleofection</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Lonza 4D Nucleofector system, programme CM150, buffer P3</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Selection/en richment strategy</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Single colony picking, genotyping by Sanger sequencing of PCR amplicons. Culture medium supplemented with HDR enhancers for 24h after nucleofection.</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">HDR enhancers TSA (10 nM, Cell Guidance Systems, cat# SM36-1) and M3814 (500 nM, Selleckchem, cat# S8586).</td></tr><tr><td valign="top" align="left" colspan="4" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000"><bold>Primers and Oligonucleotides used in this study</bold></td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"/><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000"><bold>Target</bold></td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000"><bold>Forward/Reverse primer (5â€™-3â€™)</bold></td></tr><tr><td valign="top" align="left" rowspan="4" style="border-top: 1px solid #000000;border-left: 1px solid">Sendai<break/>vector<break/>clearance<break/>RT-PCR<break/>primers</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">SeV</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">GGATCACTAGGTGATATCGAGC/<break/>ACCAGACAAGAGTTTAAGAGATATGTATC</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">KOS</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">ATGCACCGCTACGACGTGAGCGC/<break/>ACCTTGACAATCCTGATGTGG</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">KLF4</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">TTCCTGCATGCCAGAGGAGCCC/<break/>AATGTATCGAAGGTGCTCAA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">cMYC</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">TAACTGACTAGCAGGCTTGTCG/<break/>TCCACATACAGTCCTGGATGATGATG</td></tr><tr><td valign="top" align="left" rowspan="2" style="border-top: 1px solid #000000;border-left: 1px solid">Pluripotency marker qRT-PCR primers</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">OCT4</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">CGAGAGGAIIIIGAGGCTGC/<break/>CGAGGAGTACAGTGCAGTGA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">SOX2</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">GGAGCTTTGCAGGAAGTTTG/<break/>GCAAGAAGCCTCTCCTTGAA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Housekeepin g gene qRT-PCR primers</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PPIA</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">GCTTTGGGTCCAGGAATGG/<break/>GTTGTCCACAGTCAGCAATGGT</td></tr><tr><td valign="top" align="left" rowspan="7" style="border-top: 1px solid #000000;border-left: 1px solid">Genotyping<break/>primers</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS02b Q402</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AGCATTCTGGAGGTTCAAAACT/<break/>CCCAGGTCACCTTACAGTCA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS03c Y192</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">CCTTCTGTCCAATGCACCAC/<break/>ACCCTGCCTGAAGAAGTGAT</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS03d -501</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">CACAATGAAGCAAATCGCCCA/<break/>TCCCACCTCCAGCATCAAAC</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Copy number PS02b location 1</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">TGCAGCATTCTGGAGGTTCA/<break/>TCAGGCCTTGAAGTTCACTCA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Copy number PS02b location 2</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">TCCTCTGCAGTAIIIIIGAGCA/<break/>GGGTGCATTGGCTTCTGGAT</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Copy number PS02b location<break/>3</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">GCAACCATGTGAAGAGCAGTAG/<break/>GAGTGAATTTCCCAGGTCACCT</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Copy number control assay (<italic>TERT</italic>)</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">Taqman Reference Assay, Applied Biosystems cat# 4403316</td></tr><tr><td valign="top" align="left" rowspan="3" style="border-top: 1px solid #000000;border-left: 1px solid">Sequencing primers</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS02b Q402 seq</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">TGAGTGAACTTCAAGGCCTGA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">PS03c Y192 seq</td><td valign="top" align="left" colspan="2" style="border: 1px solid">CCAAACTGCACAGAGAGACG</td></tr><tr><td valign="top" align="left" style="border-left: 1px solid">PS03d -501 seq</td><td valign="top" align="left" colspan="2" style="border-left: 1px solid #000000;border-right: 1px solid">CACAATGAAGCAAATCGCCCA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">gRNA sequence</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Alt-R CRISPR-Cas9 sgRNA, PS02b Q402</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">Target:<break/>TTTTTGAGCAGTGGCTCCAA<break/>sgRNA:<break/>mU*mU*mU*rUrUrGrArGrCrArGrUrGrGrCrUrCrCrArArGrUr<break/>UrUrUrArGrArGrCrUrArGrArArArUrArGrCrArArGrUrUrArArA rArUrArArGrGrCrUrArGrUrCrCrGrUrUrArUrCrArArCrUrUrGr ArArArArArGrUrGrGrCrArCrCrGrArGrUrCrGrGrUrGrCmU*m<break/>U*mU*rU</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Genomic target sequence</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><italic>TYR</italic></td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">TYR: c.1205G&gt;A (p.Arg402Gln), chr11:89284793 (GRCh38.p14), rs1126809</td></tr><tr><td valign="top" align="left" rowspan="2" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Bioinformati c gRNA on-and-off-target binding predictions</td><td valign="top" align="left" rowspan="2" style="border-top: 1px solid #000000;border-left: 1px solid">CRISPOR</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000"><ext-link ext-link-type="uri" xlink:href="http://crispor.gi.ucsc.edu/crispor.py?batchId=oNMetAunxm">http://crispor.gi.ucsc.edu/crispor.py?batchId=oNMetAunxm</ext-link></td></tr><tr><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">cSfUDXfVwq</td></tr><tr><td valign="top" align="left" rowspan="5" style="border-top: 1px solid #000000;border-left: 1px solid">Primers for top off-target mutagenesis predicted site sequencing</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS02b OT1:<break/>ACTTTGAGCTGAGGCTCCAAT<break/>GG,<break/>chr5:166797464..166797442</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">OT1 (seqR): GACCAGTGACATGTTTGTGCC/<break/>GACCACACCCAAAGAGAAGAGA</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS02b OT2:<break/>TTTTTAAATAGTGGCTCAAAC<break/>GG, chr8:6930492..6930514</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">OT2 (seqF): TGTGTCTGGTGTTGTTGCCT/<break/>CGGCTCATGAGAAAGGTGGT</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS02b OT3:<break/>TCTTTAAGCAGAGGCCCCAAT<break/>GG,<break/>chr3:27124841..27124863</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">OT3 (seqF): CCTCTAAGGCAAGTATTACCCCC/<break/>CTATTCAGAGCAGGAGGGCC</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS02b OT4:<break/>GCTTTTGGCAGTGGCTCCAAT<break/>GG,<break/>chr9:29932785..29932763</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">OT4 (seqF): AGCACGTAGAAAAGGAGCTCC/<break/>TCTGCACATGGCTTCATCGT</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PS02b OT5:<break/>TTTTTGAGAAATGACTCAAAG GG,<break/>chr3:155102417..155102395</td><td valign="top" align="left" colspan="2" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">OT5 (seqF): GGCAACCGAAAGAGGACTGA/<break/>AGCGAAGGATCCTGCTTGTC</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">ssODN template for HDR-mediated site-directed mutagenesis</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">PS02b</td><td valign="top" align="left" colspan="2" style="border: 1px solid">5 - /Alt-R-HDR1/A*C*A ATA TGT TTC TTA GTC TGA ATA ACC TTT TCC TCT GCA GTA III IIG AGC AGT GGC TTC GAA GGC ACC GTC CTC TTC AAG AAG TTT ATC CAG AAG CCA ATG CAC CCA TTG GAC ATA A *C*C /Alt-R-HDR2/-3â€™</td></tr></tbody></table></table-wrap></floats-group></article>